Technical Analysis for MRUS - Merus N.V.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Oversold Stochastic | Weakness | 0.00% | |
New Downtrend | Bearish | 0.96% | |
Down 3 Days in a Row | Weakness | 0.96% | |
Down 4 Days in a Row | Weakness | 0.96% | |
Oversold Stochastic | Weakness | 0.96% | |
NR7 | Range Contraction | -0.63% | |
Stochastic Reached Oversold | Weakness | -0.63% | |
Down 3 Days in a Row | Weakness | -0.63% | |
Oversold Stochastic | Weakness | -0.63% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | -2.21% |
Alert | Time |
---|---|
Up 3% | about 9 hours ago |
Rose Above Previous Day's High | about 11 hours ago |
60 Minute Opening Range Breakout | about 11 hours ago |
Up 2% | about 11 hours ago |
Up 1% | about 11 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/02/2024
Merus N.V. Description
Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Solid Tumors Antibodies Cancer Immunotherapy Monoclonal Antibodies Acute Myeloid Leukemia Ovarian Cancer Myelodysplastic Syndrome Monoclonal Antibody Therapy Oncology Applications Novimmune Treatment Of Myelodysplastic Syndrome
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
View full discussion...
Indicator | Value |
---|---|
52 Week High | 52.035 |
52 Week Low | 17.16 |
Average Volume | 609,933 |
200-Day Moving Average | 28.17 |
50-Day Moving Average | 40.50 |
20-Day Moving Average | 47.22 |
10-Day Moving Average | 46.42 |
Average True Range | 2.10 |
RSI (14) | 48.98 |
ADX | 45.26 |
+DI | 17.12 |
-DI | 17.32 |
Chandelier Exit (Long, 3 ATRs) | 45.73 |
Chandelier Exit (Short, 3 ATRs) | 47.50 |
Upper Bollinger Bands | 51.42 |
Lower Bollinger Band | 43.02 |
Percent B (%b) | 0.16 |
BandWidth | 17.80 |
MACD Line | 1.19 |
MACD Signal Line | 2.25 |
MACD Histogram | -1.0648 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 46.39 | ||||
Resistance 3 (R3) | 46.47 | 45.85 | 46.05 | ||
Resistance 2 (R2) | 45.85 | 45.33 | 45.82 | 45.93 | |
Resistance 1 (R1) | 45.09 | 45.00 | 44.78 | 45.01 | 45.81 |
Pivot Point | 44.47 | 44.47 | 44.32 | 44.44 | 44.47 |
Support 1 (S1) | 43.71 | 43.95 | 43.40 | 43.63 | 42.83 |
Support 2 (S2) | 43.09 | 43.62 | 43.06 | 42.71 | |
Support 3 (S3) | 42.33 | 43.09 | 42.60 | ||
Support 4 (S4) | 42.25 |